BCL3 and prostate carcinoma: Thus the first published evidence supporting a direct role for BCL3 in drug resistance was in 2013 when a study describing elevated expression of BCL3 in prostate cancer (PC) demonstrated enhanced PC cell responses to the chemotherapeutic agents staurosporine, etoposide and paclitaxel when BCL3 was suppressed [85].